Inhibikase Therapeutics
Nasdaq IKT · Wilmington, DE
Works in Respiratory
Inhibikase Therapeutics is a clinical trial sponsor based in Wilmington, DE, listed as Nasdaq IKT. It has 2 active clinical trials with 970 planned participants, in Respiratory. Since 2021 it has completed 1 trial and stopped 1 early.
Trial track record · since 2021
Financials · Nasdaq IKT
Fundraising
Pipeline · 2 active trials
| Stage | Trial | Status |
|---|---|---|
Questions about Inhibikase Therapeutics
Inhibikase Therapeutics is lead sponsor of 2 active clinical trials on ClinicalTrials.gov, with 970 planned participants, in Respiratory. Since 2021 it has completed 1 trial and stopped 1 early.
Inhibikase Therapeutics is based in Wilmington, DE and is listed as Nasdaq IKT. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Inhibikase Therapeutics; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-09-02.
Approve Suite is not affiliated with Inhibikase Therapeutics.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.